A systematic review of dydrogesterone for the treatment of threatened miscarriage
| Autor: | Howard Carp |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Pregnancy Loss Endocrinology Diabetes and Metabolism miscarriage Administration Oral progesterone Dydrogesterone Abortion Placebo Miscarriage law.invention Endocrinology Randomized controlled trial Pregnancy law Recurrent miscarriage threatened miscarriage medicine Humans duphaston Randomized Controlled Trials as Topic Evidence-Based Medicine Obstetrics business.industry Obstetrics and Gynecology Odds ratio medicine.disease dydrogesterone Abortion Threatened Abortion Spontaneous Female Progestins business Follow-Up Studies medicine.drug |
| Zdroj: | Gynecological Endocrinology |
| ISSN: | 1473-0766 0951-3590 |
| Popis: | The objective of this systematic review was to assesses whether the orally acting progestagen, dydrogesterone lowers the incidence of subsequent miscarriage in women with recurrent miscarriage. A computerized search was performed in Medline, Embase and Ovid Medline for original reports with the product name "Duphaston" or "dydrogesterone" and limited to clinical human data. Thirteen reports of dydrogesterone treatment were identified. Two randomized trials and one non-randomized comparative trial were identified, including 509 women who fulfilled the criteria for meta-analysis. The number of subsequent miscarriages or continuing pregnancies per woman was compared in women receiving dydrogesterone compared to standard bed rest or placebo intervention. There was a 10.5% (29/275) miscarriage rate after dydrogesterone administration compared to 23.5% in control women (odds ratio for miscarriage 0.29 [confidence interval 0.13-0.65] and 13% absolute reduction in the miscarriage rate). The adverse and side effects were summarised in all 13 reports, and seemed to be minimal. Although all the predictive and confounding factors could not be controlled for, the results of this systematic review show a significant reduction of 29% in the odds for miscarriage when dydrogesterone is compared to standard care indicating a real treatment effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |